Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zai Lab Ltd ADR (NQ: ZLAB )

31.46 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 31.46
Bid (Size) 30.65 (1)
Ask (Size) 31.70 (2)
Prev. Close 31.46
Today's Range 31.46 - 31.46
52wk Range 20.98 - 53.95
Shares Outstanding 956,637,360
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Zai Lab Limited
Via Globe NewsWire
2 Unmatched Stocks Wall Street Thinks Will Soar 152% or More in the Next 2 Years
Biotechs are capable of making huge gains in short periods, and they often do. 
Via The Motley Fool

Performance

YTD
+2.01%
+2.01%
1 Month
-13.43%
-13.43%
3 Month
+3.90%
+3.90%
6 Month
-15.72%
-15.72%
1 Year
-28.21%
-28.21%

More News

Read More
Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
Via Benzinga
2 Stocks That Could Rebound and Rise 30% or More in 2023
Via The Motley Fool
Why Shares of MacroGenics Jumped Thursday
Via The Motley Fool
Earnings Scheduled For March 1, 2023
Via Benzinga
Zai Lab's Earnings: A Preview
Via Benzinga
2 Growth Stocks With Incredible Potential in the Next 5 Years
Via The Motley Fool
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Veritone, Samsara, Lexicon Pharmaceuticals And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Cano Health Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Globe NewsWire
Zai Lab Announces Participation in March Investor Conferences
From Zai Lab Limited
Via Globe NewsWire
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
From Zai Lab Limited
Via Globe NewsWire
3 More Mid-Cap Biotechs The Street Sees Doubling
Via MarketBeat
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
From Zai Lab Limited
Via Globe NewsWire
Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data
Via Benzinga
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
From Zai Lab Limited
Via Globe NewsWire
Zai Lab Announces Participation in February Investor Conferences
From Zai Lab Limited
Via Globe NewsWire
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
From Zai Lab Limited
Via Globe NewsWire
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
From Zai Lab Limited
Via Globe NewsWire
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
From Zai Lab Limited
Via Globe NewsWire
Stock Market Mostly Higher Amid Jobs Report; Tesla Price Cuts, GE Spinoff In Focus: Weekly Review
Via Investor's Business Daily
Why Shares of Zai Lab Soared This Week
Via The Motley Fool
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.